Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -0.39%67 Debt-to-EBITDA is 0.91 as of Mar. 2026, which is 139% above its 10-year median of 0.38. GuruFocus rates TSE:7096 with a GF Score™ of 67/100 and a GF Value™ of 円1,838.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 316 Biotechnology companies, StemCell Institute ranks worse than 54.43% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for StemCell Institute's Debt-to-EBITDA or its related term are showing as below:
TSE:7096'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.38 Max: 1.77
Current: 1.77
During the past 9 years, the highest Debt-to-EBITDA Ratio of StemCell Institute was 1.77. The lowest was 0.02. And the median was 0.38.
TSE:7096's Debt-to-EBITDA is ranked worse than 54.43% of 316
companies
in the Biotechnology industry
Industry Median: 1.255
vs TSE:7096: 1.77
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
StemCell Institute Debt-to-EBITDA Related Terms
StemCell Institute Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, StemCell Institute's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
StemCell Institute (TSE:7096) has a Debt-to-EBITDA of 0.91 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on StemCell Institute. This is 139% above median its historical median of 0.38. Over the past decade, StemCell Institute's Debt-to-EBITDA has ranged from 0.02 to 1.77. According to the industry distribution chart, StemCell Institute ranks #172 out of 316 companies in the Biotechnology industry, placing it in the top 54.4%.
Is StemCell Institute's Debt-to-EBITDA too high?
StemCell Institute's current Debt-to-EBITDA of 0.91 is 139% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.77. The Biotechnology industry median Debt-to-EBITDA is 1.26. StemCell Institute's value of 0.91 is 27.5% below this industry median. Based on the distribution chart, StemCell Institute ranks #172 out of 316 companies in the Biotechnology industry, which is below the industry midpoint. Overall, StemCell Institute has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #172 out of 316 companies for Debt-to-EBITDA. This places StemCell Institute in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. StemCell Institute's value of 0.91 is 27.5% below this benchmark. Historically, StemCell Institute's own Debt-to-EBITDA has ranged from 0.02 to 1.77 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 1.26, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current Debt-to-EBITDA of 0.91 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on StemCell Institute. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current Debt-to-EBITDA is 0.91, which is 139% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,838.51, compared to a current price of 円760.00 — trading 58.7% below its estimated fair value. The current Debt-to-EBITDA is 0.91, which is 139% above median its 10-year median of 0.38 and 27.5% below the Biotechnology industry median of 1.26. StemCell Institute's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Debt-to-EBITDA is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円760.00 is trading 58.7% below its estimated GF Value™ of 円1,838.51.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Debt-to-EBITDA: 0.91 (139% above median its 10-year median of 0.38)
GF Value™: 円1,838.51 vs. price of 円760.00 (58.7% below fair value)
Industry Position: 27.5% below the Biotechnology median (#172 of 316)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
67GF Score
Get the complete analysis for TSE:7096
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
